Mark Boldrin Selected Research

Glucagon-Like Peptide-1 Receptor

3/2013

The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark Boldrin Research Topics

Disease

7	Type 2 Diabetes Mellitus (MODY) 05/2017 - 07/2009
5	Weight Loss (Weight Reduction) 03/2013 - 06/2005
5	Body Weight (Weight, Body) 03/2013 - 10/2006
3	Injection Site Reaction 03/2013 - 03/2012
2	Overweight 03/2013 - 10/2006
1	Headache (Headaches) 05/2017
1	Hypoglycemia (Reactive Hypoglycemia) 05/2017
1	Nausea 03/2013
1	Vomiting 03/2013
1	Hypersensitivity (Allergy) 03/2013

Drug/Important Bio-Agent (IBA)

4	Glucose (Dextrose)FDA LinkGeneric 01/2016 - 06/2005
4	taspoglutideIBA 03/2013 - 07/2009
3	Metformin (Glucophage)FDA LinkGeneric 03/2013 - 07/2009
2	GlucokinaseIBA 05/2017 - 01/2016
2	piragliatinIBA 05/2017 - 01/2016
2	Cytochrome P-450 CYP3AIBA 05/2016 - 01/2016
2	Glucagon-Like Peptide 1 (GLP 1)IBA 12/2012 - 07/2009
1	Moxifloxacin (Avelox)FDA Link 05/2017
1	Ketoconazole (Nizoral)FDA LinkGeneric 05/2016
1	Rifampin (Rifampicin)FDA LinkGeneric 05/2016
1	Ethanol (Ethyl Alcohol)IBA 05/2016
1	Simvastatin (Zocor)FDA LinkGeneric 01/2016
1	2,4-thiazolidinedione (thiazolidinedione)IBA 03/2013
1	Exenatide (Byetta)FDA Link 03/2013
1	Glucagon-Like Peptide-1 ReceptorIBA 03/2013
1	Sitagliptin Phosphate (Januvia)FDA Link 12/2012
1	Hypoglycemic Agents (Hypoglycemics)IBA 03/2012
1	BIM 51077IBA 07/2009
1	Orlistat (Xenical)FDA Link 10/2006
1	LipidsIBA 06/2005
1	Insulin (Novolin)FDA Link 06/2005

Therapy/Procedure

4	Glycemic Control 03/2013 - 07/2009
2	Therapeutics 10/2006 - 06/2005